Literature DB >> 27592461

Adropin levels and target organ damage secondary to high blood pressure in the ED.

Bedia Gulen1, Cenker Eken2, Okkes Taha Kucukdagli3, Mustafa Serinken4, Abdurrahim Kocyigit5, Elif Kılıc6, Hüseyin Uyarel7.   

Abstract

BACKGROUND: High blood pressure is still a challenge for emergency physicians to discern the patients that require further analysis to establish the existence of acute hypertensive target organ damage (TOD). The present study aimed to reveal that adropin levels are useful for detecting TOD in patients presenting with high blood pressure.
METHODS: Patients presenting with a blood pressure of more than 180/110 mm Hg were enrolled into the study. After a resting period of 15 minutes, patients' blood pressures were measured thrice at 5-minute intervals while the patients were sitting on a chair, and the average of these measurements was accepted as the baseline value. Blood samples were obtained for either adropin levels or possible TOD during the emergency department admission.
RESULTS: A total of 119 patients were included in the study. The mean systolic and diastolic blood pressures of study patients were 204.8±23.2 and 108.3 ± 10.3, respectively, and 42% (n = 50) of the patients had TOD. Although the adropin levels were similar between the patients with or without TOD (TOD group = 195 pg/mL, interquartile range [IQR]: 178-201; no-TOD group = 196 pg/mL, IQR: 176-204 [P = .982]), it is significantly higher in normotensive patients (normotensive group = 289 pg/mL, IQR: 193-403) compared with the hypertensive ones (P < .001).
CONCLUSIONS: Despite the significantly higher levels of adropin in normotensive patients compared with hypertensive ones, adropin could not be used as a decision tool for detecting TOD in patients presenting with high blood pressure to the emergency department.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27592461     DOI: 10.1016/j.ajem.2016.04.014

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN: 0735-6757            Impact factor:   2.469


  8 in total

1.  Association between adropin and coronary artery lesions in children with Kawasaki disease.

Authors:  Maoling Yang; Qiongfei Pei; Jing Zhang; Haobo Weng; Fengchuan Jing; Qijian Yi
Journal:  Eur J Pediatr       Date:  2021-03-13       Impact factor: 3.183

2.  Inflammatory response and matrix metalloproteinases in chronic kidney failure: Modulation by adropin and spexin.

Authors:  Burak Yazgan; Filiz Avcı; Gülsün Memi; Ebru Tastekin
Journal:  Exp Biol Med (Maywood)       Date:  2021-05-22

3.  Adropin Contributes to Anti-Atherosclerosis by Suppressing Monocyte-Endothelial Cell Adhesion and Smooth Muscle Cell Proliferation.

Authors:  Kengo Sato; Tomoyuki Yamashita; Remina Shirai; Koichiro Shibata; Taisuke Okano; Maho Yamaguchi; Yusaku Mori; Tsutomu Hirano; Takuya Watanabe
Journal:  Int J Mol Sci       Date:  2018-04-26       Impact factor: 5.923

Review 4.  Adropin as A Fat-Burning Hormone with Multiple Functions-Review of a Decade of Research.

Authors:  Mariami Jasaszwili; Maria Billert; Mathias Z Strowski; Krzysztof W Nowak; Marek Skrzypski
Journal:  Molecules       Date:  2020-01-27       Impact factor: 4.411

5.  Serum Adropin Levels in Patients on Hemodialysis.

Authors:  Dijana Boric-Skaro; Maja Mizdrak; Mirko Luketin; Dinko Martinovic; Daria Tokic; Marino Vilovic; Daniela Supe-Domic; Tina Ticinovic Kurir; Josko Bozic
Journal:  Life (Basel)       Date:  2021-04-11

6.  Low serum corin levels predict end-organ damage in patients with hypertensive crisis.

Authors:  Burcu Genç Yavuz; Özgür Söğüt; Şahin Çolak; Macit Koldaş; Esma Yücetaş; Okan Bari
Journal:  Anatol J Cardiol       Date:  2021-08       Impact factor: 1.596

7.  Serum adropin levels are reduced in patients with inflammatory bowel diseases.

Authors:  Darko Brnić; Dinko Martinovic; Piero Marin Zivkovic; Daria Tokic; Ivana Tadin Hadjina; Doris Rusic; Marino Vilovic; Daniela Supe-Domic; Ante Tonkic; Josko Bozic
Journal:  Sci Rep       Date:  2020-06-09       Impact factor: 4.379

8.  Adropin Serum Levels in Patients with Primary Sjögren's Syndrome.

Authors:  Marijana Janković Danolić; Dijana Perković; Marin Petrić; Igor Barišić; Katarina Gugo; Joško Božić
Journal:  Biomolecules       Date:  2021-08-31
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.